Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H24O10 |
Molecular Weight | 388.3665 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC=C(CO)[C@@]1([H])[C@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C2C(=O)OC
InChI
InChIKey=IBFYXTRXDNAPMM-BVTMAQQCSA-N
InChI=1S/C17H24O10/c1-24-15(23)9-6-25-16(11-7(4-18)2-3-8(9)11)27-17-14(22)13(21)12(20)10(5-19)26-17/h2,6,8,10-14,16-22H,3-5H2,1H3/t8-,10-,11-,12-,13+,14-,16+,17+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25879319Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26976766
https://www.ncbi.nlm.nih.gov/pubmed/26496899
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25879319
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26976766
https://www.ncbi.nlm.nih.gov/pubmed/26496899
Geniposide, a key component extracted from the fruit of Gardenia jasminoides Ellis, is a major iridoid glycoside considered to be responsible for various biological effects of the herbs, and its aglycon is genipin. Gardenia is a widely used Chinese herb for the treatment of hepatic disease, inflammation disorders, contusions and brain disorders. Increasing studies have focused on the neuroprotective effect of geniposide in brain diseases, especially neurodegenerative disorders. Its protective effect from memory impairment and the normalization of objection recognition has been shown in animal behavioral experiments. Using a high-throughput screen for GLP-1R agonists, geniposide was identified as an agonist for GLP-1R. It has been shown that the activation of GLP-1R by geniposide induces neurotrophic and neuroprotective effects in cells. Geniposide exerted anti-inflammatory effects by interfering with the expression of P2Y14 receptor, which subsequently inhibits the downstream ERK1/2 signaling pathways and the release of the pro-inflammatory cytokines IL-8, MCP-1, IL-1β.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O35881 Gene ID: 171108.0 Gene Symbol: P2ry14 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26976766 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Differential induction of the expression of GST subunits by geniposide in rat hepatocytes. | 2004 Jan |
|
Biotransformation of geniposide by human intestinal microflora on cytotoxicity against HepG2 cells. | 2012 Mar 25 |
|
Glucagon-like peptide 1 receptor plays an essential role in geniposide attenuating lipotoxicity-induced β-cell apoptosis. | 2012 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27531366
Rats: 228.00 mg/kg geniposide by gavage
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22101168
Geniposide (0.01-100 umol/L) increased insulin secretion from INS-1 cells in a concentration-dependent manner. Geniposide (10 umol/L) enhanced acute insulin secretion in response to both the low (5.5 mmol/L) and moderately high levels (11 mmol/L) of glucose.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
107848
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY | |||
|
Geniposide
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY | |||
|
24512-63-8
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY | |||
|
145295QLXY
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY | |||
|
C007835
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY | |||
|
169799-41-1
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
DTXSID101318419
Created by
admin on Fri Dec 15 19:52:25 GMT 2023 , Edited by admin on Fri Dec 15 19:52:25 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD